94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Águeda Molinos-Quintana1*
Anna Alonso-Saladrigues2*
Blanca Herrero3Teresa Caballero-Velázquez4
Víctor Galán-Gómez5
Melissa Panesso6
Montserrat Torrebadell2Javier Delgado-Serrano4Concepción Pérez de Soto1Anna Faura2Berta González-Martínez5Ana Castillo-Robleda3
Cristina Diaz-de-Heredia6
Antonio Pérez-Martínez5José María Pérez-Hurtado1
Susana Rives7,8
José Antonio Pérez-Simón4 on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)- 1Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
- 2CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain
- 3Pediatric Hemato-Oncology Department, Peditric University Hospital del Niño Jesús, Madrid, Spain
- 4Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
- 5Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid, Madrid, Spain
- 6Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain
- 7Pediatric Cancer Center Barcelona (PCCB), Institut de Recerca Sant Joan de Déu, Leukemia and Pediatric Hematology Disorders, Developmental Tumors Biology Group, Barcelona, Spain
- 8Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red De Enfermedades Raras (CIBERER), Madrid, Spain
by Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S and Pérez-Simón JA (2024) Front. Immunol. 14:1280580. doi: 10.3389/fimmu.2023.1280580
In the published article, there was an error in the author list, and author “on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)” was erroneously excluded. The corrected author list appears below.
Águeda Molinos-Quintana1*, Anna Alonso-Saladrigues2*, Blanca Herrero3, Teresa Caballero-Velázquez4, Víctor Galán-Gómez5, Melissa Panesso6, Montserrat Torrebadell2, Javier Delgado-Serrano4, Concepción Pérez de Soto1, Anna Faura2, Berta González-Martínez5, Ana Castillo-Robleda3, Cristina Diaz-de-Heredia6, Antonio Pérez-Martínez5, José María Pérez-Hurtado1, Susana Rives7,8, José Antonio Pérez-Simón4 on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: B cell aplasia, late B-cell recovery, pre-infusion tumor burden, CD19 CART-cells, relapsed/refractory acute lymphoblastic leukemia, tisagenlecleucel, B-cell monitoring
Citation: Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S and Pérez-Simón JA (2024) Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front. Immunol. 15:1373852. doi: 10.3389/fimmu.2024.1373852
Received: 20 January 2024; Accepted: 25 January 2024;
Published: 07 February 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Molinos-Quintana, Alonso-Saladrigues, Herrero, Caballero-Velázquez, Galán-Gómez, Panesso, Torrebadell, Delgado-Serrano, Pérez de Soto, Faura, González-Martínez, Castillo-Robleda, Diaz-de-Heredia, Pérez-Martínez, Pérez-Hurtado, Rives and Pérez-Simón. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Águeda Molinos-Quintana, YWd1ZWRhLm1vbGlub3Muc3NwYUBqdW50YWRlYW5kYWx1Y2lhLmVz; YWd1ZWRhbW9saW5vc0Bob3RtYWlsLmNvbQ==; Anna Alonso-Saladrigues, YW5uYS5hbG9uc29Ac2pkLmVz